To understand the regulatory mechanisms governing glucocorticoid-mediated MYOC induction in human trabecular meshwork (HTM) cells, the expression and degradation of MYOC mRNA were quantified in HTM cells by Northern blot analysis, and the transcriptional activity of constructs containing variable lengths of putative MYOC promoters was assessed by luciferase reporter assay. Here, we confirmed that MYOC is a delayed secondary glucocorticoid-responsive gene by demonstrating that its transcription was not initiated immediately by the addition of dexamethasone (DEX) and was completely inhibited by treatment with cycloheximide. In addition, we demonstrated that MYOC mRNA is degraded very slowly, with approximately half persisting for at least 4 days, suggesting that its mRNA is intrinsically quite stable. Promoter analysis of up to 5271 base pairs upstream of MYOC revealed that luciferase induction by DEX was increased by 280 ± 34% in HTM cells. Moreover, DEX induction required the region between base pairs À2548 and À1541. However, the putative regulatory element exhibited little activity in other cell lines, including TM-5, 293A, SH-SY5Y, and human retinal pigment epithelium (RPE) cells. To our knowledge, this study provides the first evidence for the presence of a cis-acting region for secondary glucocorticoid responsiveness in the 5 0 -flanking sequences of MYOC. It will be a major step towards understanding the expression pattern of MYOC in HTM cells and TM tissue.
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Introduction
The long-term use of topical or systemic steroids results in ocular hypertension with glaucoma, known as steroid-induced glaucoma (SIG), in a subset of the normal population (Francois, 1954) . SIG is clinically identical to primary open-angle glaucoma (POAG), which affects nearly half the estimated 67 million people with glaucoma worldwide (Quigley, 1996) . Both SIG and POAG are characterized by excavation of the optic disk, visual field deficits, and optic nerve cupping, and have been shown to be caused by elevated intraocular pressure (IOP) due to increased outflow resistance through the trabecular meshwork (TM) (Armaly, 1963a (Armaly, , 1963b (Armaly, , 1966 .
The long-term exposure of TM cell cultures to dexamethasone (DEX) leads to the upregulation of a series of proteins. One of these is an acidic glycoprotein of 504 amino acids, originally referred to as trabecular meshwork-inducible glucocorticoid response (TIGR) (Nguyen et al., 1998 , Polansky, Kurtz, Alvarado, Weinreb, & Mitchell, 1989 ). The protein is currently known as myocilin, so named because its NH 2 -terminal domain resembles nonmuscle myosin (Kubota et al., 1997) . The gene encoding myocilin, MYOC, is localized on chromosome 1q23-q25 (GLC1A), and is mutated in more than 10% of cases of juvenile open-angle glaucoma (OAG) and in 3-4% of some forms of adult-onset POAG (Alward et al., 1998 , Fingert et al., 1999 , Stone et al., 1997 .
Although a great deal has been learned in recent years about the mechanisms by which mutations in MYOC cause glaucoma, much remains to be learned about the roles played by increased levels of MYOC in the TM of steroid-responsive individuals. It was initially hypothesized that MYOC upregulation might be a cause or an effect of IOP elevation in SIG because the profile of MYOC induction by DEX is in dose-and time-dependent manner very similar to the course of SIG development (Nguyen et al., 1998; Polansky et al., 1997) . However, evidence supporting the link between MYOC induction and OAG development has not as yet been available.
The present study was undertaken to characterize DEX-induced MYOC expression and to search for DEX-responsive cis-acting elements in human trabecular meshwork (HTM) cells. The characterization of MYOC expression, together with the identification of its regulatory element(s), will be a useful first step in understanding the putative relationship between DEX-mediated MYOC induction and steroid-induced ocular hypertension. (Fort Worth, TX) . Primary cultured cells from human retinal pigment epithelum (RPE) were a gift from Don-Il Ham (Sungkyunkwan University, Seoul, Korea). Human embryonic kidney 293A cells and a human neuroblastoma cell line, SH-SY5Y, were purchased from Qbiogene (Carlsbad, CA) and Cell Line Bank (Seoul, Korea), respectively. All cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and antibiotics (100 units/mL penicillin and 100 ug/mL streptomycin) at 37°C in a humidified chamber with 5% CO 2 .
Northern blot hybridization
At the end of the culture, HTM cells were harvested and total RNA was isolated using TRIzol reagent (Life Technologies, Rockville, MD). Approximately 5 ug of total RNA was size fractionated by electrophoresis on 1.2% agarose gel containing 2.2 M formaldehyde and 0.05 M 3-[N-morpholino] propane sulfonic acid (MOPS), transferred to a nylon membrane, and cross-linked with UV irradiation. The membrane was prehybridized for 2 h at 65°C in a hybridization buffer composed of 0.5 M NaH 2 PO 4 , 1 mM EDTA, 7% SDS, and 1% bovine serum albumin, and then hybridized overnight at the same temperature with a [ 32 P]-labeled probes for human MYOC and MKP-1 in the hybridization buffer. The probes used were labeled with a random primed DNA labeling kit (Amersham, Piscataway, NJ). The template DNA for MYOC was obtained by digesting the pDACMV-wild-type myocilin-GFP vector, which carries the full-length myocilin cDNA fused to the N-terminus of the green fluorescent protein gene (Sohn et al., 2002) . The gene for MKP-1 was purchased from the Korean BioInformation Center (Daejon, Korea). After hybridization, the membrane was washed twice in 2X SSC-0.1% SDS, and then in 1X SSC-0.1% SDS, and autoradiographed at À70°C using intensifying screens.
MYOC promoter-luciferase chimeric constructs
A series of luciferase reporter plasmids containing progressive deletions of the 5 0 -flanking sequence of human MYOC were made as follows. The primers used to make constructs are shown in Table  1 . Initially, 432 bp (À367 to +65), 749 bp (À684 to +65), and 1606 bp (À1541 to +65) of the 5 0 -flanking region of MYOC were amplified by polymerase chain reaction using the genomic DNA extracted from HTM cells as the template. After digestion with KpnI and NheI, the amplified products were separately cloned into the corresponding sites of the promoterless firefly luciferase expression vector, pGL3-basic (Promega), in the sense orientation. They were designated pLuc 367, pLuc 684, and pLuc 1541, respectively. To construct pLuc 2548, a 1230 bp fragment (À2548 to À1319) was amplified and cloned between the KpnI and SpeI sites of the pLuc 1541 vector. Similarly, pLuc 3531 was constructed by amplifying a 1085 bp fragment (À3531 to À2447) and cloning it into the KpnI/StuI sites of the pLuc 2548 vector. Then, a 942 bp fragment (À4351 to À3410) was amplified and cloned into the KpnI/Bst1107I sites of the pLuc 3531 vector to produce pLuc 4351. Finally, a 1012 bp fragment (À5271 to À4260) was amplified and cloned into the KpnI/NsiI sites of the pLuc 4351 vector, yielding pLuc 5271. The fidelity of all the constructs was verified by DNA sequencing.
Luciferase reporter gene analysis
Cells were plated into a 24-well plate, grown to a 60-70% confluence, and transiently transfected with 500 ng of the reporter plasmid using a novel gene delivery agent, PAMAM-Arg, which is a polyamidoamine (PAMAM) dendrimer grafted with arginine residues (Choi et al., 2004) . As an internal reference for transfection efficiency, 20 ng of pRL-TK (Promega), which expresses moderate levels of Renilla luciferase, was cotransfected. Seventy-two hours after transfection, the cells were lysed with 40 ul of passive lysis buffer (Promega) and harvested by scraping with a cell lifter. After brief centrifugation, the supernatants were recovered and subjected to consecutive assays for firefly luciferase activity and Renilla luciferase activity using the Dual-Luciferase Reporter Assay System (Promega) and a Turner Designs TD-20/20 Luminometer (Promega) according to the manufacturer's instructions.
Results
To analyze the time course of MYOC expression in vitro, primary HTM cells were cultured to confluence and exposed to 100 nM DEX for periods ranging from 12 h to 7 days. Northern blot analysis revealed that the steady-state level of MYOC mRNA increased continuously over time, but there was an apparent delay in the initiation of MYOC transcription of approximately 12 to 24 h. The delayed transcription was not noted in mitogen-activated protein kinase phosphatase 1 (MKP1), a glucocorticoid-inducible gene that is stimulated by a primary response mechanism (Fig. 1A) . It has been reported that the induction of MYOC by DEX is a secondary glucocorticoid response that shows a delayed time course compared with that of the primary response (Shepard et al., 2001) . Because the delayed secondary response acts indirectly on target gene transcription and requires de novo protein synthesis, we determined the extent to which DEX-mediated MYOC induction is blocked by cycloheximide (CHX), a protein synthesis inhibitor. In the presence of CHX, MKP1, which has a tendency to be upregulated by treatment with CHX (Aghaloo, Pirih, Shi, Bezouglaia, & Tetradis, 2006) , was induced more strongly. However, under the same conditions, no MYOC expression was observed even 4 days after induction (Fig. 1B) .
To determine the kinetics of MYOC mRNA decay in vitro, confluent HTM cells were pretreated with 100 nM DEX for 5 days and cultured in the absence of DEX for the appropriate lengths of time. At least half the MYOC mRNA was detected up to 4 days after the withdrawal of DEX, whereas MKP1 mRNA was almost entirely degraded in less than 1 day under the same conditions (Fig 2A) . It is possible that MYOC is continuously stimulated after chase because it is induced by a secondary response mechanism. To rule out this possibility, MYOC mRNA degradation was also monitored in the presence of the RNA synthesis inhibitor actinomycin D (ActD). Without its de novo synthesis, approximately half the MYOC mRNA could still be detected after 4 days following chase. In contrast, MKP1 mRNA was nearly completely degraded in less than 1 day. DEX had little effect on the steady-state level of either MYOC mRNA or MKP1 mRNA, confirming that new RNA synthesis was completely inhibited by ActD (Fig. 2B) . To identify the cis element responsible for MYOC transcription, the transient expression of a set of reporter constructs containing variable lengths of the 5 0 upstream sequence of MYOC was analyzed in the presence and absence of DEX. The differences in the luciferase activity of the lysates from untreated and DEX-treated cells are shown in Fig. 3 . Although a moderate increase in luciferase activity was observed with constructs increasing in length up to 1541 bp, a major increment in transcription activity was obtained with construct pLuc 2548, which contains 2548 bp relative to the transcriptional start site. The extent of luciferase induction by DEX did not increase further with constructs increasing in length up to 5272 bp. Therefore, the region between base pairs À2548 and À1541 in the 5 0 -flanking sequence of the MYOC gene is primarily responsible for the induction of luciferase activity by DEX. The importance of the region positioned between À2548 bp and À1541 bp, in terms of responsiveness to DEX, was identified in another HTM cell line which was isolated from an independent individual donor (data not shown). To test whether the DEXresponsive transcription observed with pLuc 2548 is specific to HTM cells, comparisons were made with other cell lines such as TM-5, 293A, SH-SY5Y, and RPE cells (Fig. 4) . A significant increase in luciferase activity with DEX treatment was observed in HTM cells, but not in the other cell lines including the primary RPE cells. These results are consistent with the earlier finding that MYOC is inducible by exposure to glucocorticoids only in cultured TM cells or TM tissues from perfused organ cultures (Nguyen et al., 1998; Polansky et al., 1997) .
Discussion
In this study, we investigated the glucocorticoid responsiveness of the glaucoma gene MYOC within several cellular contexts. We have shown here that the MYOC gene is responsive to DEX via a secondary glucocorticoid-response mechanism that is mediated by a cis-acting element located between nucleotide positions À2548 and À1541, which appears functionally active only in HTM cells. These results provides an important complement to previous findings that MYOC is a delayed secondary glucocoricoidresponsive gene that has the intriguing feature of being expressed in TM cells in vitro or TM tissues from organ cultures in vivo (Nguyen et al., 1998; Polansky et al., 1997; Shepard et al., 2001 ).
An additional important finding, in terms of MYOC expression, is the extraordinary stability of MYOC mRNA. Not only the control of the transcriptional rate, but also the modulation of mRNA stability is a key to the regulation of gene expression, determining the quantity of transcripts that are available for translation (Keene, 2007) . Generally, the half-lives of mRNAs of inducible genes are short relative to those of housekeeping genes (Lam et al., 2001 ). However, the half-life of MYOC mRNA induced by DEX is several times longer than 7.1 h, the estimated median half-life of genomes in embryonic stem cells, as calculated with microarray-based analysis (Sharova et al., 2009) . We have also reported that myocilin protein is intrinsically very stable in HTM cells and conditioned medium (Sohn et al., 2009 ). The high stability of both the mRNA and protein products of the MYOC gene explains why its expression increased continuously in DEX-treated HTM cells in proportion to the time exposed.
Although the causative role of MYOC in the pathogenesis of SIG remains controversial, some evidence suggests that the high levels of myocilin increase the eye's outflow resistance and, therefore, leads to the elevation of IOP (Fautsch et al., 2006 , Wentz-Hunter, Shen, Okazaki, Tanihara, & Yue, 2004 . On the contrary, an in vivo study revealed that, although transgenic lines expressed high MYOC levels to a degree similar to that induced by glucocorticoid, they failed to produce elevated IOP or glaucoma, suggesting that increased MYOC expression, in itself, might be insufficient to display the glaucoma phenotype (Gould et al., 2004) . Recently, we were unable to identify any clinical correlation between the potency of MYOC induction and the degree of IOP elevation among those eye drops that contain steroids (Sohn et al., 2010) . Therefore, we are hard-pressed to explain the precise relationship between MYOC expression and SIG development at this time. Nonetheless, our study shows that MYOC expression could be an important marker of the extent of exposure to glucocorticoids.
The marked responsiveness of MYOC to glucocorticoid has been well documented for more than 10 years. Consequently, certain groups have attempted to identify functional glucocorticoidresponsive region(s) in the promoter region of MYOC , Kirstein, Cvekl, Chauhan, & Tamm, 2000 Shepard et al., 2001) . To date, they have failed to identify any glucocorticoid-responsive region in the MYOC promoter, because of certain limitations in the promoter analysis of MYOC, such as the extremely low transfection efficiency of primary HTM cell cultures (Hoffman, Conley, Stamer, & McKay, 2005) . In this study, we screened different kinds of transfection reagents to optimize the transfection efficiency. Of the various reagents used, PAMAM-Arg, which is composed of a backbone of PAMAM dendrimer and a surface covered with basic L-arginine residues, worked best with cultured HTM cells (Choi et al., 2004) . Under the optimized conditions for cell transfection, our reporter construct, pLuc 2548, which contains 2548 bp relative to the transcriptional initiation site, revealed an approximately threefold increase in luciferase activity in DEXtreated cells.
However, even taking into account the low transfection efficiency of HTM cells, the transcriptional activity of pLuc 2548 was still low compared with that of other DEX-responsive genes. This suggests that the regulatory elements of MYOC may be relatively weak in terms of promoter strength, making it more difficult to identify cis-acting element in the MYOC promoter. Despite this difficulty, we identified an important regulatory region positioned between À2548 bp and À1541 bp in the 5 0 -flanking sequences of MYOC. The presence of this region led to an apparent increase in luciferase activity in DEX-treated cells. The HTM-cell-specific responsiveness of the region to DEX treatment was consistent with the results of Northern blot hybridization, indicating that our promoter analysis was reliable. It also indicates that some TM-or tissue-specific factors may be required for the cell-type-dependent transactivation of MYOC by DEX.
Until now, many investigators have focused on whether MYOC upregulation is related to SIG development. We have shown that MYOC expression alone warrants investigation beyond the scope of glaucoma research. The glucocorticoid responsiveness of MYOC has certain notable properties, including its delayed secondary responsiveness, the extraordinary stability of MYOC mRNA, and its tissue-specific inducibility. MYOC induction by DEX is definitely required for new protein synthesis from the primary response gene(s). Here, we have identified a cis-acting region for secondary glucocorticoid responsiveness on the MYOC promoter. The region may contain element(s) which bind(s) factor(s) induced by glucocorticoids. This is a major step towards understanding the distinctive pattern of MYOC expression and identifying new cis-and trans-activating elements involved in MYOC induction following glucocorticoid treatment. Further studies of MYOC expression may provide definitive clues to the role of myocilin in the pathogenesis of SIG, a role that has thus far remained elusive.
Conclusions
Our data demonstrate that DEX-induced MYOC expression is a secondary glucocorticoid response, which is mediated by a TM cellor TM-tissue-specific element(s). A region between the base pairs À2548 and À1541 in the 5 0 -flanking sequences of the MYOC includes cis-elements that are responsible for the secondary glucocorticoid response. In addition, MYOC mRNA is intrinsically quite stable, rendering an increase in transcripts in HTM cells proportional to the time of exposure to glucocorticoid. The extraordinary stability of MYOC mRNA may be an important mechanism for increasing the level of steady-state mRNA, even though its transcriptional level is low.
